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Abstract
Stereotactic percutaneous ablation is a rapidly advancing modality for treatment 
of tumors in soft solid organs such as the liver. Each year, there are about 850,000 
cases of primary liver cancer worldwide. Although surgical resection still is the gold 
standard for most cases, only 20–30% of patients are candidates for it, due to the 
advanced stage of the disease. Surgery can also be a huge burden to the patient and 
his/her quality of life might be temporarily severely reduced due to long hospital 
stays, complications, and slow recovery. To overcome these disadvantages, thermo-
ablation of tumors of up to 3 cm has become a more viable alternative especially in the 
last decade, offering a potentially equally effective but minimally invasive and tissue 
sparing treatment alternative. In conjunction with improved CT imaging, stereotactic 
image-guidance techniques and image fusion technology were introduced to increase 
safety, efficacy, and accuracy of this treatment. Stereotactic image-guidance leads to a 
simple, fast, and accurate placement of the ablation probe into the liver tumor, which 
is a prerequisite for a complete destruction of the tumor by ablation. More and more 
physicians, including surgeons, consider ablation a viable alternative to resection 
whenever feasible. Patients undergoing such a minimally invasive treatment benefit 
from a shorter hospital stays, reduced complication rates, and faster recovery.
Keywords: image-guidance, ablation, microwave/radiofrequency ablation, 
irreversible electroporation, liver tumors
1. Introduction
Thermal ablation of liver tumors is a minimally invasive locally destructive 
treatment alternative to surgical resection, which is the current gold standard for 
curative care. Not only is ablation considered for patients not amenable for surgical 
resection (<20%) but also increasingly for resectable tumors even with a curative 
intent [1–3]. Percutaneous ablation is generally performed under image-guidance 
based on CT, MRI, or ultrasound. Stereotactic image-guidance leads to a simple, 
fast, and accurate placement of the ablation needle into the liver tumor. Patients 
undergoing a percutaneous ablation benefit from an improved quality of life due to 
the shorter hospital stay compared to patients undergoing surgery [1].
Liver Cancer
2
The key challenges in percutaneous ablations are complete coverage of the tumor 
with ablation necrosis including a 5- to 10-mm margin. Insufficient coverage of the 
ablation necrosis is related to local tumor progression, which is also associated with 
poor survival prognosis. While there are many unknown factors influencing the 
ablation process, one of the prerequisites is the accurate placement of the ablation 
needle in the tumor to ablate the tumor from the inside out. Stereotactic image-
guidance aims to provide technical means to plan and accurately place an ablation 
needle into the tumor and verify its complete destruction.
1.1 Indications
For primary liver tumors (hepatocellular carcinoma, HCC), ablation is con-
sidered in cases of very early to early stage disease (BCLC 0/A) with less than 
three lesions that are smaller than 3 cm in diameter, according to the Barcelona 
Clinic Liver Cancer (BCLC) staging system guidelines [4]. For liver metastases 
from colorectal cancer (CRLM), ablation is still mostly performed for lesions not 
amenable to resection; however, first comparative studies suggest equal oncological 
outcomes (local recurrence, survival) after ablation versus resection of potentially 
resectable lesions [5]. The application as alternative to resection for HCC > 1 cm 
and CRLM is currently studied in various clinical trials; however, the oncologic 
non-inferiority of ablation has still to be confirmed in prospective trials. While the 
guidelines do not specify the access (open surgical vs. laparoscopic vs. percutane-
ous), it has been shown that the percutaneous access has lower complication rates 
and hospital stay with similar oncologic outcomes. Therefore, percutaneous abla-
tions are generally preferred over surgical ablations. However, surgical ablations are 
performed in lesions that are difficult to target percutaneously or when ablation is 
combined with surgical resection. Stereotactic image-guidance offers a procedure to 
accurately target a lesion percutaneously, even in very difficult cases, in a predict-
able time.
In recent years, studies have been conducted to show that stereotactic image-guid-
ance also allows to treat larger lesions by combining multiple ablation zones to fully 
cover the lesion [6], and also as an option for downstaging or bridging candidates for 
liver transplantation [7]. Larger lesions can also be treated with transcatheter arterial 
chemoembolization (TACE), but complete necrosis is barely achieved due to incom-
plete embolization and tumor angiogenesis. Therefore, approaches have been studied 
where TACE is combined with thermal ablation for HCCs >3 cm and found a syner-
getic effect [8]. For this combined treatment approach, an image-guidance approach 
has also been proposed, and preliminary animal experiments conducted [9].
1.2 Available image-guidance systems
There are currently three stereotactic image-guidance systems available on the 
market. The CAS-One IR (CAScination AG, Switzerland) and IMACTIS (IMACTIS, 
France) systems are pure image-guidance systems, whereas the MAXIO (Perfint, 
India) is a system with an integrated robotic arm for needle alignment. There are 
also several research devices in use in specialized clinics and it is expected that more 
devices will be available in the future.
1.3 Ablation modalities
Tumor ablation is defined as the local delivery of thermal, chemical, or elec-
trical energy to a specific tumor in order to achieve its complete destruction. 
The most commonly used ablation techniques in conjunction with stereotactic 
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image-guidance are thermal, chemical, and electrical ablation, which are described 
in the following sections.
1.3.1 Thermal ablation
Radiofrequency ablation (RFA) refers to energy sources that generate energy 
within the RF spectrum between 300 and 500 KHz. The RF electrode destroys all 
the cells at the target zone by heating up the tissue as a result of a high alternating 
electrical field that oscillates in the high-frequency range [10]. In Microwave abla-
tions (MWA), a high-frequency electromagnetic field in the range of 900 MHz–2.45 
Ghz forces water molecules to continuously realign, which results in high kinetic 
energy that is converted to heat in the tissue. Both RFA and MWA techniques 
destroy the tumor cells by coagulation necrosis using heat above 60°C. Compared to 
RFA, MWA heats the tissue faster due to the different heat distribution and there-
fore is also less affected by adjacent vessels (heat sink effect) [11, 12].
To date, most evidence supporting local ablation for small HCC lesions is based 
on works reporting RFA treatment and the comparison of RFA versus surgical 
resection. However, more recently, the theoretical and clinical advantages of MWA 
have often been highlighted. These include shorter application times, and the gen-
eration of higher temperatures resulting in larger ablation zones. Currently, several 
works comparing RFA versus MWA have reported partially contradicting results, 
especially regarding local tumor control after bot treatments [13, 14]. Overall, it can 
be assumed that no significant difference between RFA and MWA regarding overall 
and recurrent-free survival in patients with HCC exists [15]. However, there seems 
to be a tendency toward superiority of MWA regarding local recurrence rates in 
larger tumors as well as regarding operating times.
Cryoablation destroys tissue with freezing temperatures, alternating freezing 
and thawing or slight heating. The rapid freezing of tissue disrupts the cellular 
membranes by direct intracellular ice crystal formation. The most commonly used 
cooling agents are argon gas or liquid nitrogen [16].
1.3.2 Chemical ablation
Percutaneous ethanol injection (PEI) is the most commonly employed chemical 
ablation technique, but was demonstrated to have inferior results to thermal abla-
tion [17]. PEI denaturizes the cellular proteins through cytoplasmic dehydration, 
which eventually also causes local coagulation necrosis. However, when compared 
to the other techniques, PEI shows significant disadvantages such as high local 
tumor progression rate, unpredictable ablation volumes, and lower overall survival 
rates.
1.3.3 Irreversible electroporation
Irreversible electroporation (IRE) is non-thermal ablation technique that deliv-
ers short pulses of high-voltage electrical energy directly to a tumor. This technique 
disrupts the cell membrane irreversibly and induces cell death by apoptosis (also 
known as natural cell death). The advantage of IRE is that it preserves blood vessels 
and therefore there is a high incentive to use IRE especially where vital structures 
and blood vessels can be easily damaged by thermal ablation methods [18]. IRE 
requires placing multiple needles in parallel and at a specific configuration and 
distance and therefore stereotactic image-guidance provides a precise placement of 
the needles. As IRE is a relatively new treatment, there are also less data available 
about its outcomes.
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2. Components of a stereotactic image-guidance system
In this chapter, the general components of stereotactic image-guidance devices 
are described. In general, such a system consists of (Figure 1):
a. a tracking system that measures the position and orientation of the patient and 
the instruments in 3D space
b. software packages for
• trajectory and ablation planning
• trajectory and ablation validation
• visualization aids for needle placement
c. an alignment device that allows an accurate placement of the ablation needle 
into the tumor
2.1 Tracking systems
The tracking system measures the position and orientation of the needle guid-
ance device and the patient in space. There are currently two different tracking 
modalities used for these procedures, namely optical and electromagnetic tracking. 
Optical tracking systems use a stereo infrared camera and locate retroreflecting 
spheres mounted on a rigid body— the so-called marker shields. Based on the 
geometry of these marker shields, the camera is able to identify them (e.g., needle 
guidance device). The second tracking modality is electromagnetic tracking, 
which generates an electromagnetic field and measures the current induced into 
small coils, which are attached to the device [19]. The position and orientation of 
the instrument are calculated from the current and a chip attached to the sensor 
provides information for identification.
Figure 1. 
Components and setup of a stereotactic image-guidance system.
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Optical tracking systems tend to be more accurate but have the problem of a 
line-of-sight. Therefore, if the line-of-sight is occluded (e.g., by blood, radiologists’ 
hand), the tracking device will lose track of the marker. Electromagnetic tracking 
relies on a known magnetic field and therefore is heavily affected by ferromagnetic 
and electrically conducting materials. Therefore, which system to use heavily 
depends on the target environment where the system will be used.
2.1.1 Patient tracking
A stereotactic image-guidance system needs to know where the patient is located 
relative to the tracking device in order to calculate the position of the needle guid-
ance device relative to the planned needle trajectory (Figure 2). One option is to 
place retroreflective spheres on the patient that are detectable by the optical track-
ing system [20]. These spheres are also detectable on the CT scan and can therefore 
be used to register the CT to the patient [21]. Another approach, typically used with 
EM-based systems, is to place a position sensor on the patient’s abdomen, which can 
be detected by the EM-tracking system. Both methods allow to track the patient in 
space. However, organ deformations due to breathing or repositioning of the patient 
cannot be calculated by these tracking methods. Nevertheless, when using multiple 
spheres or sensors, large deformations can be recognized, which allows to display a 
warning to the user.
2.2 Navigation software
The navigation software consists of planning tools, validation tools, and visu-
alization aids for the radiologist to accurately align the needle guide and place the 
ablation needle.
2.2.1 Trajectory and ablation planning software
With the trajectory planning component, the radiologist plans trajectories to 
the tumor and also estimates the amount of energy needed to successfully ablate 
the tumor. In the most basic form, the software allows to plan a single straight-line 
trajectory to the tumor. In a more advanced setting, the software compensates for 
the offset between the needle tip and the active zone (which depends on the type of 
ablation device) and also supports multi-needle ablations with overlapping ablation 
Figure 2. 
(left) Patient tracking method using multiple retroreflective spheres (right) or using a single EM position sensor 
(© IMACTIS).
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zones [6]. A trajectory for an ablation consists of a target point (tumor center) and 
an entry point on the skin. Depending on the location of the tumor, this trajectory 
passes nearby critical structures (e.g., major blood vessels, ribs) where specialized 
views along the needle trajectory are used to keep sufficient distance from these 
structures.
In cases where the tumor is not visible on the CT scan or the contrast agent can-
not be administered to the patient, a pre-operative MRI scan can be fused with the 
intra-operative CT. The image-guidance system then allows to plan the trajectory on 
the MRI scan and then calculates the location on the CT scan.
2.2.2 Navigation visualization
The visualization component for navigation typically consists of a crosshair 
viewer and/or CT slice with a real-time overlay of the needle trajectory. This allows 
the radiologist to align the needle guidance device with the planned trajectory and 
then to place the needle at the correct depth. An indication of the deformation 
or motion of the patient is also visualized for monitoring and estimation of the 
accuracy.
2.2.3 Ablation validation
The ablation validation component fuses the pre- and post-ablation CT scans 
and visualizes them using alpha blending. The radiologist can switch between the 
pre- and post-ablation scan by choosing the blending level. More advanced systems 
allow to segment the tumor and the ablation zone and present a coverage.
2.3 Needle guidance devices
2.3.1 Freehand stereotactic navigation
With freehand navigation, a position sensor is attached to the ablation needle 
and the position and orientation of the needle are measured by the tracking device. 
The radiologist can freely move the needle and the navigation screen helps to place 
the needle according to the defined plan.
2.3.2 Stereotactic arms
When using a stereotactic arm (Figure 3), the tracking device measures the 
position and orientation of the needle guide in the stereotactic arm and uses this 
information to guide the radiologist. Such an arm typically has multiple handles, 
which allow to adjust and lock each degree of freedom separately. With this, 
the radiologist first aligns the arm roughly to the entry point on the skin and 
then pulls the handle to lock the position of the stereotactic arm. The remaining 
handles can then be used to fine-adjust the orientation to exactly align the device 
to follow the planned trajectory. Once the trajectory is aligned, the needle can be 
placed through the needle guide with the depth that is indicated on the navigation 
screen [22].
Another advantage of the stereotactic arm is that it holds the needle in place 
during a control CT scan and during the ablation procedure. This prevents move-
ment of the needle, which would result in an uncontrolled ablation and potential 
tissue damage. Because the stereotactic arm holds the ablation needle during the 
control CT scan, the radiologist does not need to be in the CT room and thus is also 
not exposed to radiation [23].
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2.3.3 Robotic devices
These devices are motorized articulated arms for alignment of ablation needles, 
providing a 6-dimensional alignment of a trajectory with respect to the target. The 
radiologist delivers the needle by hand and the robots passively guide it. There is a 
commercial provider, which has shown superior results in terms of accuracy and 
precision when compared to freehand targeting [24]. The findings from pre-clinical 
models and also from available clinical data show that passive needle guidance 
robots do not significantly increase available accuracy compared to stereotactic 
arms. Therefore, it is rather a matter of choice which kind of system to use.
3. Procedure
In the following chapter, a typical workflow (Figure 4) for a stereotactic image-
guided percutaneous ablation of a liver tumor is presented.
3.1 Patient preparation
An important part when applying stereotactic guidance is that the organ of 
interest is properly fixated. In the case of the liver, that not only means to fixate 
the patient but also reduce the motion of the liver due to breathing. The fixation of 
the patient is generally done using a vacuum mattress. Once the patient is under 
Figure 3. 
Stereotactic arm during the adjustment of the needle trajectory.
Figure 4. 
Workflow of a percutaneous ablation of a liver tumor using stereotactic image-guidance.
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Figure 5. 
Planning of a trajectory and the optimal ablation energy through an inter-costal trajectory.
anesthesia, the vacuum mattress is pressed toward the patient and the vacuum 
applied. This will prevent the patient from moving on the CT table.
To minimize the motion of the liver due to breathing, there are a number of 
alternatives:
• Apnea: where the ventilation is stopped on the ventilation device to hold a 
predefined air pressure inside the lung.
• Tube disconnection: where the endotracheal tube is disconnected from the 
ventilation device and all air is exhaled from the lungs.
• High-frequency jet ventilation (HFJV): where short pulses of small volumes 
of pressurized air are delivered with high respiratory rates. This technique of 
mechanical ventilation results in minimal movement of lung and abdominal 
organs and is feasible for long durations [25]
Apnea and tube disconnection are applied during the CT scans and during the 
needle placement, while during the rest of the procedure, normal ventilation is 
applied. Jet ventilation can be applied during the whole procedure or also only dur-
ing the CT scans and the needle placement.
3.1.1 Marker for patient tracking
Before starting the procedure, the patient tracker has to be placed on the 
patient’s abdomen. Depending on the system, there are also specific requirements 
on how and where to place these markers for optimal accuracy of the system.
3.2 Trajectory planning
A trajectory for an ablation consists of a target point (the center of the tumor) 
and an entry point (entry on the skin) (Figure 5). Most ablation systems do not 
have their active center (the center of the ablation) at the tip. Therefore, the ablation 
system and the needle type can be selected, and the navigation system then com-
putes a modified trajectory, such that the center of the ablation is in the center of the 
tumor. Additional to the trajectory, software guidance can also support the decision 
of the time and energy level to apply during the ablation. To avoid the puncture of 
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blood vessels or other organs at risk, the navigation system presents a slice of the CT 
scan along the planned trajectory. This is especially useful in ablations in the superior 
segments where usually a sub- or inter-costal trajectory is required.
In case the tumor is not visible on the CECT scan, a pre-operative MRI scan can 
be fused with the intra-operative CT scan. The trajectory can then be planned on 
the MRI scan and the navigation system calculates the position of the trajectory 
on the intra-operative CT scan. One thing to consider is that the liver might have 
deformed with respect to the MRI scan depending on the positioning of the patient. 
Therefore, it is crucial to visually assess the accuracy of the fusion before planning a 
trajectory.
3.3 Navigated needle placement
During the navigated needle placement, the radiologist aligns the stereotactic 
arm with the planned trajectory according to the crosshair viewer. Additionally, 
the system presents a real-time overlay of the needle trajectory on the CT scan 
(Figure 6). Once the stereotactic arm is aligned, the needle can be placed into the 
tumor according to the depth information on the display.
Depending on the patient tracking method, the system presents a real-time 
estimation of the deformation of the organ and stops the navigation display if the 
estimated deformation is too large.
3.4 Needle validation
To ensure correct needle position before applying the energy of the ablation 
needle, a non-enhanced CT scan is acquired and fused with the planning scan by 
the navigation system. The image-guidance system then either detects the needle 
automatically or the radiologist selects it manually. Based on this selection and the 
planned trajectory, the needle placement accuracy is measured and displayed on the 
screen (Figure 7). If the placement accuracy is insufficient (>3 mm), the radiologist 
would repeat the needle placement step.
Figure 6. 
Crosshair viewer with the orientation and depth aid for accurate placement and a real-time CT slice along the 
current trajectory.
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In lesions that are close to critical structures (vena cava, heart, etc.), the needle 
can be placed at three-fourths of the final depth and correct orientation can be mea-
sured on the needle validation scan before the needle is inserted into the final target.
3.5 Ablation
Once correct needle placement is confirmed, the energy is applied by the abla-
tion device. The amount of energy needed can also be planned with the planning 
software. However, recent studies have shown that the resulting ablation zones 
differ from the prediction based on the ex-vivo results that are provided by the abla-
tion device manufacturers [26] and also depend on the tumor type [27].
3.6 Ablation validation
In this step, the radiologist evaluates the coverage of the tumor by the ablation 
necrosis, which has been shown to be an independent predictor in determining local 
Figure 8. 
Ablation zone validation with the tumor on the pre-ablation scan (left) and the ablation necrosis on the post-
ablation scan (right).
Figure 7. 
Needle validation on a CT slice along the actual needle trajectory.
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tumor recurrence with a larger ablation margin resulting in a lower risk of local 
tumor recurrence [28]. The ablation coverage and margin are evaluated by visual 
assessment where the radiologist compares the pre- and post-ablation scans, which 
can be displayed side-by-side on a radiological screen or overlaid with transpar-
ency (Figure 8). An image-guidance system or external software can display the 
segmented tumor and the planned ablation margin, which makes the visual abla-
tion validation more accurate, reproducible, and less subjective by providing visual 
markers and boundaries. If the radiologist identifies residual tumor or insufficient 
margin on the fused pre- and post-ablation scan, then another ablation is per-
formed in the same procedure. Therefore, a new trajectory is planned based on the 
post-ablation scan to also cover the remaining tumor.
4. Current evidence and future perspectives
Using stereotactic ablation reduces the exposure to radiation and procedure time 
while improving the needle placement accuracy at the same time [29]. The inter-
ventional radiologist can leave the CT room during the acquisition, and therefore 
is not exposed to ionizing radiation at all. There are also large retrospective studies 
showing the potential benefits and applications of stereotactic image-guided abla-
tions. While these studies do not show better oncological outcomes when using ste-
reotactic ablation over conventional ablation, they state that the number of patients 
treated with a curative intent largely increased with the introduction of stereotactic 
guidance [1, 30, 31]. Furthermore, it has been shown in case-reports that stereotaxy 
was especially useful in very difficult cases when the tumor would not be reachable 
with conventional CT guidance [32].
Despite the current evidence showing that stereotactic image-guidance improves 
ablation needle accuracy and reduces procedure time and radiation dose, the abla-
tion treatment itself has limitations, which are part of the current research—both 
clinical and engineering research.
4.1 Ablation of larger tumors
One of the short-term improvements of thermal ablations is the reproducible 
ablation of tumors larger than 3 cm. Current evidence shows that the LTP rate is 
higher in tumors larger than 3 cm and therefore such tumors are not recommended 
to treat with ablation [30, 33]. There are studies reporting larger ablation zones 
when using multiple needles in parallel, which could cover tumors larger than 3 cm 
[34]. With stereotactic image-guidance, such treatments can be delivered more 
reproducibly [6]. However, using multiple needles heavily increases the cost for the 
procedure at some institutions, which can be a major limitation.
4.2 Ablation zone prediction
The planning of the ablation employs the information from the ablation device 
manufactures’ brochures, which presents the expected ablation necrosis that can 
be obtained for a specific energy delivered. The ablation model presented in the 
brochures is described as an ellipsoidal or spherical volume, which was obtained 
from measuring the ablation necrosis in ex-vivo, non-perfused, healthy animal liv-
ers. Recent studies have shown that the in-vivo ablation volumes differ significantly 
from the ex-vivo data, with the in-vivo ablation volumes being much smaller than 
the ex-vivo data predicts [26, 35]. Future models will be based on retrospective in-
vivo data and also take any clinical parameters into account, such as the pathology 
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of the tissue, the patient’s clinical background, other treatments being administered 
(e.g., chemotherapy), and the influence of adjacent blood vessels on the expansion 
of the ablation volume.
4.3 Quantitative ablation assessment
Recently, there has been a high interest in quantitative ablation assessment to 
decrease the local tumor progression rates by ensuring complete ablation coverage 
and sufficient (<5mm) ablation margin using 3D image analysis software [36]. 
There are several studies that have attempted to describe the ablation success or 
coverage using numerical metrics derived from 3D tumor and ablation segmenta-
tions based on a follow-up scan at 4–8 weeks after ablation [37]. However, a fast 
intra-operative tool for assessing the ablation outcome would enable an immediate 
re-ablation and achievement of complete tumor destruction in the same treatment 
session. The Ablation fit (Ablation-fit, Italy) software is currently the only software 
available on the market for intra-operative quantitative 3D ablation assessment. 
However, evidence of the predictive value of intra-operative assessment is still 
limited as it has been evaluated only at a single center so far and due to the unknown 
tissue shrinkage after thermal ablation treatment [38].
4.4 Robotics
As in other disciplines in medicine, robotics will also be introduced in inter-
ventional oncology on a larger scale. While there are robotic devices available for 
stereotactic ablations, these are merely motorized arms for alignment. The radiolo-
gist still has to be sterile at the CT table and place the needle by hand. However, the 
future most likely will go toward autonomous robots that plan the trajectory, place 
the needle, and choose the right amount of energy for ablation. The radiologist 
might then be able to control the procedure in the control CT room monitoring and 
approving the robots’ decisions [39–41].
5. Conclusion
In conclusion, stereotactic image-guidance provides technical support for 
accurately planning and placing ablation needles at the desired location and verify-
ing the complete destruction of the tumor. These highly complex systems not only 
decrease radiation dose, contrast, and needle punctures, but also give a predictable 
procedure time even in technical challenging cases, which allows to optimally allo-
cate the resources in an interventional radiology suite and most importantly offers 
the patient a safe and efficient minimally invasive procedure.
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